IODAX Pharma AG

IODAX Pharma AG is at the forefront of biotechnology research, bridging the gap between classical pharmacology and therapeutic radiation physics. With proven execution know-how, IODAX Pharma AG is innovating medicine by focusing on halogens to address future supply chain and nuclide cost issues in the rapidly developing radiopharmaceutical industry.

IODAX Pharma AG is dedicated to leveraging the unique synergies of industry key players to make radiopharmaceuticals a clinical reality. Halogen-labeled compounds can directly enter cells via the membrane, opening the intracellular space for a combined radiopharmacological intervention. IODAX Pharma AG is embedded in the Saxonian NukliD® cluster, driving advancements in cancer therapy development and radiopharmaceuticals.

Through strategic drug licensing and partnerships, IODAX Pharma AG is committed to pushing the boundaries of biotechnology research and pharmaceutical investments. IODAX Pharma AG continues to expand its capabilities, ensuring cutting-edge solutions and therapies for patients. We invite the manager of IODAX Pharma AG to create a customized and exclusive company showcase and product listing on our platform.